Doxorubicin-induccd cardiomyopathy from the cardiotoxic mechanisms to management

被引:707
作者
Takemura, Genzou [1 ]
Fujiwara, Hisayoshi [1 ]
机构
[1] Gifu Univ, Sch Med, Dept Internal Med 2, Gifu 5011194, Japan
关键词
D O I
10.1016/j.pcad.2006.10.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
First isolated in the early 1960s, doxorubicin (DOX) remains among the most effective anticancer drug ever developed. However, this drug has proven to be a double-edged sword because it also causes a cardiomyopathy that leads to a form of congestive heart failure that is usually refractory to common medications. It is hoped that a better understanding of the mechanisms underlying DOX's cardiotoxicity will enable development of therapies with which to prevent and/or treat the heart failure it causes. Suggested contributors to DOX-induced cardiomyopathy include formation of reactive oxygen species, apoptosis, inhibited expression of cardiomyocyte-specific genes, and altered molecular signaling. And taking these various contributors into consideration, a variety of approaches aimed at preventing or mitigating the cardiotoxicity of DOX have been tried, but so far, the ability of these treatments to protect the heart from damage has been limited. That said, one recent approach that shows promise is adjuvant therapy with a combination of hematopoietic cytokines, including erythropoietin, granulocyte colony-stimulating factor, and thrombopoietin. We suggest this approach to preventing DOX-induced cardiomyopathy is worthy of serious consideration for clinical use. © 2007.
引用
收藏
页码:330 / 352
页数:23
相关论文
共 192 条
[1]   Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials [J].
Alberts, DS ;
Muggia, FM ;
Carmichael, J ;
Winer, EP ;
Jahanzeb, M ;
Venook, AP ;
Skubitz, KM ;
Rivera, E ;
Sparano, JA ;
Dibella, NJ ;
Stewart, SJ ;
Kavanagh, JJ ;
Gabizon, AA .
SEMINARS IN ONCOLOGY, 2004, 31 (06) :53-90
[2]   FREE-RADICALS INDUCED BY ADRIAMYCIN-SENSITIVE AND ADRIAMYCIN-RESISTANT CELLS - A SPIN-TRAPPING STUDY [J].
ALEGRIA, AE ;
SAMUNI, A ;
MITCHELL, JB ;
RIESZ, P ;
RUSSO, A .
BIOCHEMISTRY, 1989, 28 (21) :8653-8658
[3]   SERIAL ASSESSMENT OF DOXORUBICIN CARDIOTOXICITY WITH QUANTITATIVE RADIONUCLIDE ANGIOCARDIOGRAPHY [J].
ALEXANDER, J ;
DAINIAK, N ;
BERGER, HJ ;
GOLDMAN, L ;
JOHNSTONE, D ;
REDUTO, L ;
DUFFY, T ;
SCHWARTZ, P ;
GOTTSCHALK, A ;
ZARET, BL .
NEW ENGLAND JOURNAL OF MEDICINE, 1979, 300 (06) :278-283
[4]   INDUCTION OF APOPTOSIS IN CHRONIC MYELOGENOUS LEUKEMIA LYMPHOCYTES BY HYDROXYUREA AND ADRIAMYCIN [J].
ANAND, S ;
VERMA, H ;
KUMAR, L ;
SINGH, N .
CANCER LETTERS, 1995, 88 (01) :101-105
[5]  
ARENA E, 1979, ARZNEIMITTEL-FORSCH, V29-1, P901
[6]  
ARICO M, 1988, NEW ENGL J MED, V319, P1353
[7]   Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity [J].
Aries, A ;
Paradis, P ;
Lefebvre, C ;
Schwartz, RJ ;
Nemer, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (18) :6975-6980
[8]  
Arola OJ, 2000, CANCER RES, V60, P1789
[9]   NADPH CYTOCHROME-P-450 REDUCTASE ACTIVATION OF QUINONE ANTI-CANCER AGENTS TO FREE-RADICALS [J].
BACHUR, NR ;
GORDON, SL ;
GEE, MV ;
KON, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1979, 76 (02) :954-957
[10]  
BACHUR NR, 1982, CANCER RES, V42, P1078